| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.86 [0.67, 1.10] | | < 1 | | 0% | 1 study (1/-) | 88.3 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.57 [0.45, 0.73] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 6.11 [2.77, 13.47] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 0.56 [0.34, 0.93] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.44 [0.25, 0.76] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.85 [0.32, 2.25] | | < 1 | | 0% | 1 study (1/-) | 63.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.46 [0.40, 5.25] | | < 1 | | 0% | 1 study (1/-) | 28.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.10 [0.01, 0.81] | | < 1 | | 0% | 1 study (1/-) | 98.4 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.96 [0.06, 15.48] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.96 [0.06, 15.48] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.48 [0.02, 14.37] | | < 1 | | 0% | 1 study (1/-) | 66.2 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.16 [0.01, 3.17] | | < 1 | | 0% | 1 study (1/-) | 88.3 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.23 [0.05, 1.11] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.93 [0.06, 57.80] | | < 1 | | 0% | 1 study (1/-) | 35.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.17] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.93 [0.06, 57.80] | | < 1 | | 0% | 1 study (1/-) | 35.5 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.93 [0.17, 21.50] | | < 1 | | 0% | 1 study (1/-) | 29.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.12 [0.01, 2.24] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.01, 5.32] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.93 [0.06, 57.80] | | < 1 | | 0% | 1 study (1/-) | 35.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.12 [0.01, 2.24] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 1 study (1/-) | 89.9 % | NA | not evaluable | | non important | - |
